Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC).

@article{Brooks2009PhaseIS,
  title={Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC).},
  author={Heather D. Brooks and Bonnie S. Glisson and Chunhua Lu and Anita L. Sabichi and Faye M. Johnson and L E Ginsberg and Benjamin Nebiyou Bekele and Vassiliki A. Papadimitrakopoulou},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 15_suppl},
  pages={6022}
}
6022 Background: Dasatinib is a potent inhibitor of src-family kinases, ephA2, PDGFR, Abl, and c-kit. A single-center, open-label, phase II trial was conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of dasatinib in recurrent or metastatic HNSCC. METHODS Pts with measurable disease by RECIST, who received 0 or 1 prior regimen for recurrent or metastatic HNSCC with an ECOG performance status 0-1 and tumor tissue appropriate for IHC and FISH were eligible… CONTINUE READING